top of page

Our history

The Prague-based biotechnological start-up Elphogene, Inc. has received an initial investment from i&i Prague in order to implement its oncoMonitor, a liquid biopsy technology into a commercial assay for non-invasive diagnostic monitoring of patients in advanced stages colorectal cancer.

The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute, a leading Czech private research center widely recognized for its strong record of scientific projects in clinical cancer genomics.

Originally developed at Genomac and now exclusively owned by Elphogene, the oncoMonitor liquid biopsy technology, will further be developed and validated in a clinical setting at company headquarters and laboratories located near Prague Vaclav Havel airport in Ruzyne.

bottom of page